– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

“The characteristics of NET vary widely from patient to patient, and very few treatment options have demonstrated the ability to improve outcomes across such a heterogeneous population,” said Jennifer ...

Carcinoid syndrome: This is caused by a carcinoid tumor, which is a type of neuroendocrine tumor ... However, regular fevers or losing weight without trying, especially if accompanied by night sweats, ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Chan, clinical director of the Gastrointestinal Cancer Center and director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute in Boston, led the trial. She spoke ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. "It was encouraging to see that ...

clinical director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute, said in a statement in September.

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Other specific hormones related to clinical syndromes are gastrin for Zollinger–Ellison syndrome ... Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor.